Table 1.
Patient characteristics at enrollment by molecular subtype
| Subtype 1 (N = 105) | Subtype 2 (N = 127) | p-value+ | |
|---|---|---|---|
| Age | 70.08 (8.07) | 69.33 (7.62) | 0.31 |
| Sex | 0.16 | ||
| M | 83 (79.1%) | 89 (70.1%) | |
| F | 22 (21.0%) | 38 (30.0%) | |
| Ever smoker | 0.59 | ||
| Y | 73 (69.5%) | 83 (65.4%) | |
| N | 32 (30.5%) | 44 (34.7%) | |
| History of coronary artery disease (including prior MI)* | 1.0 | ||
| Y | 33 (31.4%) | 39 (31.0%) | |
| N | 72 (68.6%) | 87 (69.1%) | |
| History of COPD* | 1.0 | ||
| Y | 19 (18.1%) | 22 (17.5%) | |
| N | 86 (81.9%) | 104 (82.5%) | |
| History of diabetes* | 0.18 | ||
| Y | 24 (22.9%) | 19 (15.1%) | |
| N | 81 (77.1%) | 107 (84.9%) | |
| Antifibrotic treatment | 0.07 | ||
| Nintedanib | 24 (22.9%) | 18 (14.17%) | |
| Pirfenidone | 41 (38.1%) | 43 (33.86%) | |
| Neither | 40 (39.1%) | 66 (52.0%) | |
| DLCO % predicted | 38.31 (12.46) | 43.09 (14.69) | 0.01 |
| FVC % predicted | 67.89 (15.18) | 73.82 (17.72) | 0.02 |
| FEV1% predicted | 76.09 (16.11) | 81.03 (20.00) | 0.12 |
| CPI [34] | 55.77 (9.93) | 51.21 (11.49) | 0.01 |
| Diagnostic category [40] | 0.41 | ||
| Definite IPF | 77 (73.3%) | 95 (74.8%) | |
| Probable IPF | 22 (21.0%) | 29 (22.8%) | |
| Possible IPF | 6 (5.7%) | 3 (2.4%) | |
| GAP stage [39] | 0.15 | ||
| 1 | 22 (21.0%) | 40 (31.5%) | |
| 2 | 64 (61.0%) | 71 (55.9%) | |
| 3 | 19 (18.1%) | 16 (12.6%) |
Data are mean (SD) or n (%). Abbreviations: MI: Myocardial infarction, DLco: Diffusing capacity of the lungs for carbon monoxide, FVC: Forced vital capacity, FEV1: Forced expiratory volume in the first second, CPI: Composite physiologic index.
*One subject in subtype 1 was missing medical history.
+Kruskal-Wallis test compared continuous variables and Chi-square test compared categorical variables.